# CADENCE: sotatercept verlaagt pulmonale vaatweerstand bij gecombineerde pulmonale hypertensie bij HFpEF

*geplaatst 2026-04-25 · Algemeen · Circulation · doi https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079918 · https://hartvaat.nl/2026/03/29/cadence-sotatercept-verlaagt-pulmonale-vaatweerstand-bij-gecombineerde-pulmonale/*

In deze fase 2, placebo-gecontroleerde trial (n=164) verlaagde sotatercept de pulmonale vaatweerstand na 24 weken bij patiënten met gecombineerde post- en pre-capillaire pulmonale hypertensie geassocieerd met HFpEF. De mediane placebo-gecorrigeerde daling was het grootst in de 0,3 mg/kg-groep. Tot nu bestond er geen bewezen therapie voor deze CpcPH–HFpEF-populatie, die zowel cardiale als pulmonale vasculaire remodeling vertoont.

## English: 

In this phase 2, placebo-controlled trial (n=164), sotatercept lowered pulmonary vascular resistance at week 24 in patients with combined post- and pre-capillary pulmonary hypertension associated with HFpEF. The median placebo-adjusted decline was largest in the 0.3 mg/kg arm. Until now no proven therapy existed for this CpcPH–HFpEF population, which involves remodeling in both the heart and pulmonary vasculature.

## Abstract (original, from the publication)

Background: Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction (CpcPH–HFpEF) involves remodeling in both the heart and pulmonary vasculature. Despite significant mortality, there are no proven therapies.Methods: In this multicenter, randomized, placebo-controlled, phase 2 trial, adults received sotatercept (0.3 or 0.7 mg/kg) or placebo every 3 weeks. The primary end point was change in pulmonary vascular resistance at week 24. Hodges–Lehmann shift estimates described placebo-adjusted changes.Results: 164 patients were randomized 54:55:55 to sotatercept 0.3 mg/kg, 0.7 mg/kg, and placebo, and baseline median pulmonary vascular resistance was 5.2 (interquartile range [IQR] 4.0–6.9) Wood units. The median change from baseline in pulmonary vascular resistance at week 24 was –0.67 Wood units in the sotatercept 0.3 mg/kg group, –0.33 Wood units in the sotatercept 0.7 mg/kg group, and 0.26 Wood units in the placebo group. The Hodges–Lehman

Auteurs: Mardi Gomberg

---
Bron: Circulation, https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079918. Bijgewerkt 2026-07-03T13:31:43Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.